Sage Therapeutics, Inc.
NASDAQ:SAGE
Overview | Financials
Company Name | Sage Therapeutics, Inc. |
Symbol | SAGE |
Currency | USD |
Price | 6.31 |
Market Cap | 386,003,523 |
Dividend Yield | 0% |
52-week-range | 5.64 - 28.26 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Barry E. Greene |
Website | https://www.sagerx.com |
An error occurred while fetching data.
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD